Cited by 1,575Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Open access

Phan, Giao Q., Yang, James C., Sherry, Richard M., Hwu, Patrick, Topalian, Suzanne L., Schwartzentruber, Douglas J., Restifo, Nicholas P., Haworth, Leah R., Seipp, Claudia A., Freezer, Linda J., Morton, Kathleen E., Mavroukakis, Sharon A., Duray, Paul H., Steinberg, Seth M., Allison, James P., Davis, Thomas A., Rosenberg, Steven A.·2003·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.1533209100PMC PMC166236

Open this paper in CoChat — free account

Abstract

Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is a critical immunoregulatory molecule (expressed on activated T cells and a subset of regulatory T cells) capable of down-regulating T cell activation. Blockade of CTLA-4 has been shown in animal models to improve the effectiveness of cancer immunotherapy. We thus treated 14 patients with metastatic melanoma by using serial i.v. administration of a fully human anti-CTLA-4 antibody (MDX-010) in conjunction with s.c. vaccination with two modified HLA-A*0201-restricted peptides from the gp100 melanoma-associated antigen, gp100:209-217(210M) and gp100:280-288(288V). This blockade of CTLA-4 induced grade III/IV autoimmune manifestations in six patients (43%), including dermatitis, enterocolitis, hepatitis, and hypophysitis, and mediated objective cancer regression in three patients (21%; two complete and one partial responses). This study establishes CTLA-4 as an important molecule regulating tolerance to "self" antigens in humans and suggests a role for CTLA-4 blockade in breaking tolerance to human cancer antigens for cancer immunotherapy.

Integrity signals

Registry

Crossref · 10.1073/pnas.1533209100

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Self-citation
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
CD4+CD25+ Immunoregulatory T Cells Suppress Polyclonal T Cell Activation In Vitro by Inhibiting Interleukin 2 Production
Thornton, A. M., & Shevach, E. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.2.287 · Cited by 2,637
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation
Read, S., Malmström, V., & Powrie, F. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,206
A cell culture model for T lymphocyte clonal anergy
Schwartz, R. H. (1990) · Science · doi:10.1126/science.2113314 · Cited by 1,857
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., et al. (1998) · Nature Medicine · doi:10.1038/nm0398-321 · Cited by 1,786
Self-citation
A Theory of Self-Nonself Discrimination
Bretscher, P., & Cohn, M. (1970) · Science · doi:10.1126/science.169.3950.1042 · Cited by 1,755
CTLA-4 is a second receptor for the B cell activation antigen B7.
Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L. S., Damle, N. K., & Ledbetter, J. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.3.561 · Cited by 1,685
A new member of the immunoglobulin superfamily—CTLA-4
Brunet, J., Denizot, F., Luciani, M., Roux-Rouquié, M., Suzan, M., Mattéi, M., & Golstein, P. (1987) · Nature · doi:10.1038/328267a0 · Cited by 1,307

Show all 38 references

Research works printed but not linked: 4

Alegre, M. L., Frauwirth, K. A. & Thompson, C. B. (2002) Nat. Rev. Immunol. 1, 220-228.
Hurwitz, A. A., Foster, B. A., Kwon, E. D., Truong, T., Choi, E. M., Greenberg, N. M., Burg, M. B. & Allison, J. P. (2000) Cancer Res. 60, 2444-2448.10811122
Pass, H. A., Schwarz, S. L., Wunderlich, J. R. & Rosenberg, S. A. (1998) Cancer J. Sci. Am. 4, 316-323.9815296
Angelini, G., Gardella, S., Ardy, M., Ciriolo, M. R., Filomeni, G., Di Trapani, G., Clarke, F., Sitia, R. & Rubartelli, A. (2002) Proc. Natl. Acad. Sci. USA 99, 1471-1476.

Sorted by citations

Items 301–400 of 1,000

Engineering opportunities in cancer immunotherapy
Jeanbart, L., & Swartz, M. A. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1508516112 · Cited by 133
Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment
Dalmazi, G. D., Ippolito, S., Lupi, I., & Caturegli, P. (2019) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2019.1701434 · Cited by 134
Intratumoral Immune Cell Infiltrates, FoxP3, and Indoleamine 2,3-Dioxygenase in Patients with Melanoma Undergoing CTLA4 Blockade
Ribas, A., Comı́n-Anduix, B., Economou, J. S., Donahue, T. R., de la Rocha, P., Morris, L. F., Jalil, J., Dissette, V. B., Shintaku, I. P., Glaspy, J. A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0783 · Cited by 132
Regulatory T cells in human disease and their potential for therapeutic manipulation
Taams, L. S., Palmer, D. B., Akbar, A. N., Robinson, D. S., Brown, Z., & Hawrylowicz, C. M. (2006) · Immunology · doi:10.1111/j.1365-2567.2006.02348.x · Cited by 135
Tumor Vaccines Expressing Flt3 Ligand Synergize with CTLA-4 Blockade to Reject Preimplanted Tumors
Curran, M. A., & Allison, J. P. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3289 · Cited by 132
Self-citation
Harnessing the immune system to treat cancer
Bhardwaj, N. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32136 · Cited by 133
Clinical effects of in situ photoimmunotherapy on late-stage melanoma patients
Li, X., Naylor, M. F., Le, H., Nordquist, R. E., Teague, T. K., Howard, C. A., Murray, C. K., & Chen, W. R. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.11.13434 · Cited by 131
Phase I/II Trial of an Allogeneic Cellular Immunotherapy in Hormone-Naive Prostate Cancer
Simons, J. W., Carducci, M. A., Mikhak, B., Lim, M. K., Biedrzycki, B. A., Borellini, F., Clift, S., Hege, K. M., Ando, D. G., Piantadosi, S., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0145 · Cited by 131
Immune Response Against Dying Tumor Cells
Zitvogel, L., Casares, N., Péquignot, M. O., Chaput, N., Albert, M. L., & Kroemer, G. (2004) · Advances in immunology · doi:10.1016/s0065-2776(04)84004-5 · Cited by 137
Ipilimumab-induced Ocular and Orbital Inflammation—A Case Series and Review of the Literature
Papavasileiou, E., Prasad, S., Freitag, S. K., Sobrin, L., & Lobo, A. (2015) · Ocular Immunology and Inflammation · doi:10.3109/09273948.2014.1001858 · Cited by 128
Targeting Tregs in Malignant Brain Cancer: Overcoming IDO
Wainwright, D. A., Dey, M., Chang, A. L., & Lesniak, M. S. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00116 · Cited by 134
What Is the Role of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade in Patients with Metastatic Melanoma?
Robert, C., & Ghiringhelli, F. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0028 · Cited by 128
STAT3 Activation in Glioblastoma: Biochemical and Therapeutic Implications
Kim, J., Patel, M. A., Ruzevick, J., Jackson, C. M., & Lim, M. K. (2014) · Cancers · doi:10.3390/cancers6010376 · Cited by 128
MAGE-A1-, MAGE-A10-, and gp100-Derived Peptides Are Immunogenic When Combined with Granulocyte-Macrophage Colony-Stimulating Factor and Montanide ISA-51 Adjuvant and Administered as Part of a Multipeptide Vaccine for Melanoma
Chianese‐Bullock, K. A., Pressley, J., Garbee, C. F., Hibbitts, S., Murphy, C., Yamshchikov, G. V., Petroni, G. R., Bissonette, E. A., Neese, P. Y., Grosh, W. W., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.5.3080 · Cited by 126
Blocking Programmed Death-1 Ligand-PD-1 Interactions by Local Gene Therapy Results in Enhancement of Antitumor Effect of Secondary Lymphoid Tissue Chemokine
He, Y., Zhang, G., Wang, X., Zhang, H., Yuan, Y., Li, D., & Feng, Z. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.8.4919 · Cited by 125
Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice
Du, X., Liu, M., Su, J., Zhang, P., Tang, F., Ye, P., Devenport, M., Wang, X., Zhang, Y., Liu, Y., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0012-z · Cited by 123
Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment
Govindaraj, C., Scalzo‐Inguanti, K., Madondo, M., Hallo, J., Flanagan, K. L., Quinn, M. A., & Plebanski, M. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.07.003 · Cited by 125
Eradication of melanomas by targeted elimination of a minor subset of tumor cells
Schmidt, P., Kopecky, C., Hombach, A. A., Zigrino, P., Mauch, C., & Abken, H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009069108 · Cited by 129
Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors
Blaise, D. (2003) · Blood · doi:10.1182/blood-2003-07-2236 · Cited by 123
Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy
Zhang, Y., Du, X., Liu, M., Tang, F., Zhang, P., Ai, C., Fields, J. K., Sundberg, E. J., Latinovic, O., Devenport, M., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0184-1 · Cited by 123
Cancer and myositis: new insights into an old association
Levine, S. M. (2006) · Current Opinion in Rheumatology · doi:10.1097/01.bor.0000245721.02512.77 · Cited by 122
Mechanisms of Spatial and Temporal Development of Autoimmune Vitiligo in Tyrosinase-Specific TCR Transgenic Mice
Gregg, R. K., Nichols, L. A., Chen, Y., Lu, B., & Engelhard, V. H. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902778 · Cited by 121
Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management
Barroso‐Sousa, R., Ott, P. A., Hodi, F. S., Kaiser, U. B., Tolaney, S. M., & Min, L. (2018) · Cancer · doi:10.1002/cncr.31200 · Cited by 122
Antibody and antibody fragments for cancer immunotherapy
Chen, W., Yang, Y., & Jiang, X. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.08.021 · Cited by 123
Adoptive Transfer of Vaccine-Induced Peripheral Blood Mononuclear Cells to Patients with Metastatic Melanoma following Lymphodepletion
Powell, D. J., Dudley, M. E., Hogan, K., Wunderlich, J. R., & Rosenberg, S. A. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.9.6527 · Cited by 120
Self-citation
Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy
Johnson, B. F., Clay, T. M., Hobeika, A. C., Lyerly, H. K., & Morse, M. A. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.4.449 · Cited by 121
Co-signaling molecules of the B7-CD28 family in positive and negative regulation of T lymphocyte responses
Wang, S., & Chen, L. (2004) · Microbes and Infection · doi:10.1016/j.micinf.2004.03.007 · Cited by 119
CD4 regulatory T cells in human cancer pathogenesis
Knutson, K. L., Disis, M. L., & Salazar, L. G. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0194-y · Cited by 122
Role of Dendritic Cell Phenotype, Determinant Spreading, and Negative Costimulatory Blockade in Dendritic Cell-Based Melanoma Immunotherapy
Ribas, A., Glaspy, J. A., Lee, Y., Dissette, V. B., Seja, E., Vu, H. T., Tchekmedyian, N. S., Oseguera, D. K., Comin-Anduix, B., Wargo, J. A., et al. (2004) · Journal of Immunotherapy · doi:10.1097/00002371-200409000-00004 · Cited by 120
Skin Reactions in a Subset of Patients With Stage IV Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen 4 Monoclonal Antibody as a Single Agent
Jaber, S. H., Cowen, E. W., Haworth, L. R., Booher, S. L., Berman, D. M., Rosenberg, S. A., & Hwang, S. T. (2006) · Archives of Dermatology · doi:10.1001/archderm.142.2.166 · Cited by 119
Self-citation
Dendritic cell vaccines in melanoma: From promise to proof?
Lesterhuis, W. J., Aarntzen, E. H. J. G., de Vries, I. J. M., Schuurhuis, D. H., Figdor, C. G., Adema, G. J., & Punt, C. J. A. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.12.007 · Cited by 119
Immune dysregulation in human immunodeficiency virus infection: know it, fix it, prevent it?
Boasso, A., Shearer, G. M., & Chougnet, C. A. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.02043.x · Cited by 118
MECHANISMS IN ENDOCRINOLOGY: Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review
Juszczak, A., Gupta, A., Karavitaki, N., Middleton, M. R., & Grossman, A. B. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0167 · Cited by 117
Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
Wang, W., Yu, D., Sarnaik, A. A., Yu, B., Hall, M. S., Morelli, D., Zhang, Y., Zhao, X., & Weber, J. S. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-146 · Cited by 122
Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti–CTLA-4 antibodies
Lute, K. D., May, K. F., Lu, P., Zhang, H., Kocak, E., Mosinger, B., Wolford, C. C., Phillips, G. S., Caligiuri, M. A., Zheng, P., et al. (2005) · Blood · doi:10.1182/blood-2005-06-2298 · Cited by 118
Cutaneous manifestations associated with immune checkpoint inhibitors
Watanabe, T., & Yamaguchi, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1071983 · Cited by 117
A simple method to cure established tumors by inflammatory killing of normal cells
Daniels, G. A., Sanchez-Perez, L. A., Díaz, R. M., Kottke, T. J., Thompson, J., Lai, M., Gough, M. J., Karim, M., Bushell, A., Chong, H., et al. (2004) · Nature Biotechnology · doi:10.1038/nbt1007 · Cited by 117
Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells
Wei, W., Morris, G. P., & Kong, Y.-C. M. (2003) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-003-0444-1 · Cited by 119
Intratumoral regulatory T cells: markers, subsets and their impact on anti-tumor immunity
Yano, H., Andrews, L. P., Workman, C. J., & Vignali, D. A. A. (2019) · Immunology · doi:10.1111/imm.13067 · Cited by 116
Pretreatment frequency of circulating IL‐17+CD4+ T‐cells, but not Tregs, correlates with clinical response to whole‐cell vaccination in prostate cancer patients
Derhovanessian, E., Adams, V., Hähnel, K., Groeger, A., Pandha, H., Ward, S., & Pawelec, G. (2009) · International Journal of Cancer · doi:10.1002/ijc.24497 · Cited by 122
Macrophage and Tumor Cell Cross-Talk Is Fundamental for Lung Tumor Progression: We Need to Talk
Sarode, P., Schaefer, M. B., Grimminger, F., Seeger, W., & Savai, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00324 · Cited by 116
Optimal Management of Metastatic Melanoma: Current Strategies and Future Directions
Batus, M., Waheed, S., Ruby, C. E., Petersen, L. F., Bines, S. D., & Kaufman, H. L. (2013) · American Journal of Clinical Dermatology · doi:10.1007/s40257-013-0025-9 · Cited by 117
Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma
Weinstock, M., & McDermott, D. F. (2015) · Therapeutic Advances in Urology · doi:10.1177/1756287215597647 · Cited by 119
Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors
Day, D., & Hansen, A. R. (2016) · BioDrugs · doi:10.1007/s40259-016-0204-3 · Cited by 117
Immunotherapy in the treatment of non-small cell lung cancer
Sundar, R., Soong, R., Cho, B. C., Brahmer, J. R., & Soo, R. A. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.05.005 · Cited by 114
Increased Prevalence of Regulatory T Cells (Treg) is Induced by Pancreas Adenocarcinoma
Liyanage, U. K., Goedegebuure, P. S., Moore, T. T., Viehl, C. T., Moo‐Young, T. A., Larson, J. W., Frey, D. M., Ehlers, J. P., Eberlein, T. J., & Linehan, D. C. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000205644.43735.4e · Cited by 113
The role of STAT3 in glioblastoma progression through dual influences on tumor cells and the immune microenvironment
Chang, N., Ahn, S. H., Kong, D., Lee, H. W., & Nam, D. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.01.004 · Cited by 117
Interleukin‐10 in viral diseases and cancer: exiting the labyrinth?
Vicari, A. P., & Trinchieri, G. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00216.x · Cited by 111
An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies
Schönfeld, D. L., Matschiner, G., Chatwell, L., Trentmann, S. M., Gille, H., Hülsmeyer, M., Brown, N., Kaye, P. M., Schlehuber, S., Hohlbaum, A. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813399106 · Cited by 110
A Pilot Study of IL-2Rα Blockade during Lymphopenia Depletes Regulatory T-cells and Correlates with Enhanced Immunity in Patients with Glioblastoma
Sampson, J. H., Schmittling, R. J., Archer, G. E., Congdon, K. L., Nair, S. K., Reap, E. A., Desjardins, A., Friedman, A. H., Friedman, H. S., Herndon, J. E., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031046 · Cited by 109
Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with hematologic or solid neoplasms: A systematic review
Garant, A., Guilbault, C., Ekmekjian, T., Greenwald, Z. R., Murgoi, P., & Vuong, T. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.10.009 · Cited by 111
European recommendations for management of immune checkpoint inhibitors‐derived dermatologic adverse events. The EADV task force ‘Dermatology for cancer patients’ position statement
Apalla, Z., Nikolaou, V. A., Fattore, D., Fabbrocini, G., Freites‐Martínez, A., Sollena, P., Lacouture, M. E., Kraehenbuehl, L., Stratigos, A., Peris, K., et al. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17855 · Cited by 108
Improving Antitumor Immune Responses by Circumventing Immunoregulatory Cells and Mechanisms
Lizee, G. A., Radvanyi, L. G., Overwijk, W. W., & Hwu, P. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0944 · Cited by 109
Self-citation
Novel immune check point inhibiting antibodies in cancer therapy—Opportunities and challenges
Diesendruck, Y., & Benhar, I. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.02.001 · Cited by 107
Influence of Cytotoxic T Lymphocyte-associated Antigen 4 (CTLA4) Common Polymorphisms on Outcome in Treatment of Melanoma Patients With CTLA-4 Blockade
Breunis, W. B., Tarazona‐Santos, E., Chen, R., Kiley, M., Rosenberg, S. A., & Chanock, S. J. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31817fd8f3 · Cited by 107
Self-citation
Ipilimumab in the treatment of metastatic melanoma: management of adverse events
Scarpati, G. D. V., Fusciello, C., Perri, F., Sabbatino, F., Carlomagno, C., Pepe, S., & Ferrone, S. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s57335 · Cited by 106
Molecular control of regulatory T cell development and function
Kitagawa, Y., & Sakaguchi, S. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.10.002 · Cited by 112
Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
Mullinax, J. E., Hall, M. S., Prabhakaran, S., Weber, J. S., Khushalani, N. I., Eroglu, Z., Brohl, A. S., Markowitz, J., Royster, E. B., Richards, A. D., et al. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00044 · Cited by 106
Tumor-specific CD4+ Melanoma Tumor-infiltrating Lymphocytes
Friedman, K. M., Prieto, P. A., Devillier, L., Gross, C. A., Yang, J. C., Wunderlich, J. R., Rosenberg, S. A., & Dudley, M. E. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31825898c5 · Cited by 106
Self-citation
CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab?
Menard, C., Ghiringhelli, F., Roux, S., Chaput, N., Mateus, C., Grohmann, U., Caillat‐Zucman, S., Zitvogel, L., & Robert, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4797 · Cited by 106
Concurrent Induction of Antitumor Immunity and Autoimmune Thyroiditis in CD4+CD25+ Regulatory T Cell–Depleted Mice
Wei, W., Jacob, J. B., Zielinski, J. F., Flynn, J. C., Shim, K. D., Alsharabi, G., Giraldo, A. A., & Kong, Y.-C. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0934 · Cited by 106
Modeling and predicting clinical efficacy for drugs targeting the tumor milieu
Singh, M., & Ferrara, N. (2012) · Nature Biotechnology · doi:10.1038/nbt.2286 · Cited by 107
TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals
Manfredi, F., Cianciotti, B. C., Potenza, A., Tassi, E., Noviello, M., Biondi, A., Ciceri, F., Bonini, C., & Ruggiero, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01689 · Cited by 108
Dual Relationship Between Stromal Cells and Immune Cells in the Tumor Microenvironment
Mun, J.-Y., Leem, S., Lee, J. H., & Kim, H. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.864739 · Cited by 113
Immunogenicity, Including Vitiligo, and Feasibility of Vaccination With AutologousGM-CSF–Transduced Tumor Cells in Metastatic Melanoma Patients
Luiten, R. M., Taanman-Kueter, E. W., Mooi, W. J., Gallee, M. P. W., Rankin, E. M., Gerritsen, W. R., Clift, S., Nooijen, W. J., Weder, P., van de Kasteele, W., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.6816 · Cited by 105
The Impact of the Microbiome on Resistance to Cancer Treatment with Chemotherapeutic Agents and Immunotherapy
Ševčíková, A., Izoldova, N., Števurková, V., Kasperova, B., Chovanec, M., Čierniková, S., & Mego, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23010488 · Cited by 109
The Role of Tregs in Glioma-Mediated Immunosuppression: Potential Target for Intervention
Humphries, W. E., Wei, J., Sampson, J. H., & Heimberger, A. B. (2009) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2009.08.012 · Cited by 103
Harnessing cancer immunotherapy during the unexploited immediate perioperative period
Matzner, P., Sandbank, E., Neeman, E., Zmora, O., Gottumukkala, V. N. R., & Ben‐Eliyahu, S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0319-9 · Cited by 104
Immunotherapy of Cancer by Targeting Regulatory T cells
Chen, B.-J., Zhao, J., Zhang, D., Zheng, A.-H., & Wu, G. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108469 · Cited by 107
Overcoming Immunologic Tolerance to Melanoma: Targeting CTLA-4 with Ipilimumab (MDX-010)
Weber, J. S. (2008) · The Oncologist · doi:10.1634/theoncologist.13-s4-16 · Cited by 103
Interleukin 21: combination strategies for cancer therapy
Skak, K., Kragh, M., Hausman, D. F., Smyth, M. J., & Sivakumar, P. V. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2482 · Cited by 102
Several immune escape patterns in non-Hodgkin's lymphomas
Laurent, C., Charmpi, K., Gravelle, P., Tosolini, M., Franchet, C., Ysebaert, L., Brousset, P., Bidaut, A., Ycart, B., & Fournié, J. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1026530 · Cited by 101
Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center
Lisberg, A. E., Tucker, D. A., Goldman, J. W., Wolf, B., Carroll, J., Hardy, A., Morris, K. K., Linares, P., Adame, C. R., Spiegel, M. L., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0063 · Cited by 102
GM-CSF Gene-Modifed Cancer Cell Immunotherapies: Of Mice and Men
Hege, K. M., Jooss, K. U., & Pardoll, D. M. (2006) · International Reviews of Immunology · doi:10.1080/08830180600992498 · Cited by 101
Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy
Francis, D. M., & Thomas, S. N. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.011 · Cited by 100
Melan-A–specific Cytotoxic T Cells Are Associated with Tumor Regression and Autoimmunity Following Treatment with Anti-CTLA-4
Klein, O., Ebert, L. M., Nicholaou, T., Browning, J., Russell, S. E., Zuber, M., Jackson, H. M., Dimopoulos, N., Tan, B. S., Hoos, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2424 · Cited by 100
Regulatory T cells and tumour immunity – observations in mice and men
Gallimore, A., & Godkin, A. J. (2007) · Immunology · doi:10.1111/j.1365-2567.2007.02748.x · Cited by 101
Enhanced Survival Associated with Vitiligo Expression during Maintenance Biotherapy for Metastatic Melanoma
Boasberg, P. D., Hoon, D. S. �., Piro, L. D., Martin, M. A., Fujimoto, A., Kristedja, T. S., Bhachu, S., Ye, X., Deck, R., & O'Day, S. J. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700545 · Cited by 99
Dendritic Cell-Based Immunotherapy
Osada, T., Clay, T. M., Woo, C. Y., Morse, M. A., & Lyerly, H. K. (2006) · International Reviews of Immunology · doi:10.1080/08830180600992456 · Cited by 99
Immune Checkpoint Blockade
Naidoo, J., Page, D. B., & Wolchok, J. D. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.02.002 · Cited by 102
Targeting Costimulatory Molecules to Improve Antitumor Immunity
Capece, D., Verzella, D., Fischietti, M., Zazzeroni, F., & Alesse, E. (2012) · BioMed Research International · doi:10.1155/2012/926321 · Cited by 103
Effective Cancer Therapy Through Immunomodulation
Waldmann, T. A. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104549 · Cited by 97
Angiogenesis and the Tumor Vasculature as Antitumor Immune Modulators: The Role of Vascular Endothelial Growth Factor and Endothelin
Kandalaft, L. E., Motz, G. T., Busch, J. I., & Coukos, G. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_95 · Cited by 97
Metronomic Chemotherapy Enhances Antitumor Effects of Cancer Vaccine by Depleting Regulatory T Lymphocytes and Inhibiting Tumor Angiogenesis
Chen, C., Ho, C., Chang, M., Sun, W.-Z., Chen, Y., Chiang, Y., Syu, M.-H., Hsieh, C., & Cheng, W. (2010) · Molecular Therapy · doi:10.1038/mt.2010.34 · Cited by 96
Refractory Colitis Following Anti-CTLA4 Antibody Therapy: Analysis of Mucosal FOXP3+ T Cells
Lord, J. D., Hackman, R. C., Moklebust, A., Thompson, J. A., Higano, C. S., Chielens, D., Steinbach, G., & McDonald, G. B. (2009) · Digestive Diseases and Sciences · doi:10.1007/s10620-009-0839-8 · Cited by 95
Paraneoplastic autoimmune multiorgan syndrome: Review of the literature and support for a cytotoxic role in pathogenesis
Billet, S. E., Grando, S. A., & Pittelkow, M. R. (2006) · Autoimmunity · doi:10.1080/08916930600972099 · Cited by 95
Positive and Negative Regulation of Cellular Immune Responses in Physiologic Conditions and Diseases
Viganó, S., Perreau, M., Pantaleo, G., & Harari, A. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/485781 · Cited by 96
CTLA-4 blockade increases antigen-specific CD8+ T cells in prevaccinated patients with melanoma: three cases
Yuan, J. D., Ginsberg, B., Page, D. B., Li, Y., Rasalan, T. S., Gallardo, H. F., Xu, Y., Adams, S., Bhardwaj, N., BUSAM, K. J., et al. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1011-9 · Cited by 94
Self-citation
Anti-CD25 Antibody Enhancement of Vaccine-Induced Immunogenicity: Increased Durable Cellular Immunity with Reduced Immunodominance
Moore, A., Gallimore, A., Draper, S. J., Watkins, K. R., Gilbert, S. C., & Hill, A. V. S. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.11.7264 · Cited by 94
New Strategies in Bladder Cancer: A Second Coming for Immunotherapy
Ghasemzadeh, A., Bivalacqua, T. J., Hahn, N. M., & Drake, C. G. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1135 · Cited by 93
Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies
Jennings, J. J., Mandaliya, R. H., Nakshabandi, A., & Lewis, J. H. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1574744 · Cited by 94
Premature cell senescence in human skin: Dual face in chronic acquired pigmentary disorders
Bellei, B., & Picardo, M. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100981 · Cited by 93
Regulatory T Cells in Radiotherapeutic Responses
Schaue, D., Xie, M. W., Ratikan, J. A., & McBride, W. H. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00090 · Cited by 98
Stat3 as a Potential Target for Cancer Immunotherapy
Kortylewski, M., & Yu, H. (2007) · Journal of Immunotherapy · doi:10.1097/01.cji.0000211327.76266.65 · Cited by 94
The complex role of B7 molecules in tumor immunology
Seliger, B., Marincola, F. M., Ferrone, S., & Abken, H. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.09.010 · Cited by 93
The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy
Leung, J., & Suh, W. (2014) · Immune Network · doi:10.4110/in.2014.14.6.265 · Cited by 92
Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes
Waldron-Lynch, F., & Herold, K. C. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3402 · Cited by 96
Diversity and Recognition Efficiency of T Cell Responses to Cancer
Stuge, T. B., Holmes, S., Saharan, S., Tuettenberg, A., Roederer, M., Weber, J. S., & Lee, P. P. (2004) · PLoS Medicine · doi:10.1371/journal.pmed.0010028 · Cited by 92
Marked Differences in Human Melanoma Antigen-Specific T Cell Responsiveness after Vaccination Using a Functional Microarray
Chen, D. S., Soen, Y., Stuge, T. B., Lee, P. P., Weber, J. S., Brown, P. O., & Davis, M. M. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020265 · Cited by 91
T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment
Santegoets, S. J. A. M., Stam, A. G. M., Lougheed, S. M., Gall, H. E., Scholten, P. E. T., Reijm, M., Jooss, K. U., Sacks, N., Hege, K. M., Lowy, I., et al. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1330-5 · Cited by 94

Authors: Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., Morton, K. E., Mavroukakis, S. A., Duray, P. H., Steinberg, S. M., Allison, J. P., Davis, T. A., & Rosenberg, S. A.
Affiliations: National Institutes of Health (US)
Surgery Branch, Laboratory of Pathology, and Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892; Howard Hughes Medical Institute, Department of Molecular and Cell Biology, University of California, Berkeley, CA 94720; and Medarex, Inc., Princeton, NJ 08540
ORCID: Phan, Giao Q.
Yang, James C.
Sherry, Richard M.
Hwu, Patrick
Topalian, Suzanne L.
Restifo, Nicholas P.
Mavroukakis, Sharon A.
Steinberg, Seth M.
Allison, James P.
Davis, Thomas A.
Rosenberg, Steven A.
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2003-06-25
Volume: 100
Issue: 14
Pages: 8372-8377
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.1533209100
PMC: PMC166236
OpenAlex: W2134638467
Cited by: 1,575
References: 38
Citations by year: 2026: 10 · 2025: 11 · 2024: 26 · 2023: 41 · 2022: 48 · 2021: 52 · 2020: 58 · 2019: 56 · 2018: 68 · 2017: 82 · 2016: 58 · 2015: 72 · 2014: 70 · 2013: 78 · 2012: 72
FWCI: 46.70
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (Z99 CA999999)
National Cancer Institute (Z01BC010763)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: CTLA-4 blockade, metastatic melanoma, autoimmunity, tumor regression, anti-CTLA-4 antibody, HLA-A*0201, cancer immunotherapy, self-tolerance, regulatory T cells, T cell activation, enterocolitis, hypophysitis, hepatitis, skin inflammation
MeSH terms: Adult, Antibodies, Monoclonal, Antibodies, Neoplasm, Antigens, Differentiation, Antigens, Neoplasm, Autoimmune Diseases, Colitis, Dermatitis, Female, Humans, Immune Tolerance, Immunotherapy, Injections, Intravenous, Injections, Subcutaneous, Lymphocyte Activation, Male, Melanoma, Membrane Glycoproteins, Middle Aged, Neoplasm Metastasis, Neoplasm Proteins, Peptide Fragments, Peptides, T-Lymphocytes, Cytotoxic, Vaccination, Vitiligo, Antigens, CD, HLA-A2 Antigen, T-Lymphocyte Subsets, Salvage Therapy, Hepatitis, Autoimmune, gp100 Melanoma Antigen, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks